Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shingo Takada

Showing results (181-190 of 183) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 183 results.
International Journal of Clinical Oncology|September 2, 2024
Clinical outcomes of first-line combination therapy with immune checkpoint inhibitor for metastatic non-clear cell renal cell carcinoma: a multi-institutional retrospective study in JapanAkihiro Yoshimura, Taigo Kato, Yasutomo Nakai, et al.
Cancer Science|December 4, 2024
Comparative analysis of gut microbiota in hormone-sensitive and castration-resistant prostate cancer in Japanese menSaizo Fujimoto, Koji Hatano, Eri Banno, et al.
Scientific Reports|December 12, 2025
Real-world efficacy and safety of pembrolizumab plus lenvatinib in patients with metastatic renal cell carcinoma: a multi-institutional retrospective studyTaigo Kato, Yasutomo Nakai, Mototaka Sato, et al.
Pageof 19

Showing results (181-190 of 183) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 183 results.
International Journal of Clinical Oncology|September 2, 2024
Clinical outcomes of first-line combination therapy with immune checkpoint inhibitor for metastatic non-clear cell renal cell carcinoma: a multi-institutional retrospective study in JapanAkihiro Yoshimura, Taigo Kato, Yasutomo Nakai, et al.
Cancer Science|December 4, 2024
Comparative analysis of gut microbiota in hormone-sensitive and castration-resistant prostate cancer in Japanese menSaizo Fujimoto, Koji Hatano, Eri Banno, et al.
Scientific Reports|December 12, 2025
Real-world efficacy and safety of pembrolizumab plus lenvatinib in patients with metastatic renal cell carcinoma: a multi-institutional retrospective studyTaigo Kato, Yasutomo Nakai, Mototaka Sato, et al.
Pageof 19